Overview

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Status:
Recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related acute myeloid leukemia.

Phase:

Phase 2

Details

Lead Sponsor:

University of California, Irvine

Collaborators:

Jazz Pharmaceuticals
Pfizer

Treatments:

Cytarabine
Daunorubicin